ORCID

https://orcid.org/0009-0008-1509-5264

Year

2025

Season

Fall

Paper Type

Master's Thesis

College

College of Arts and Sciences

Degree Name

Master of Science in Biology (MS)

Department

Biology

NACO controlled Corporate Body

University of North Florida. Department of Biology

Committee Chairperson

Dr. Marie Mooney

Second Advisor

Dr. David Waddell

Third Advisor

Dr. Judith Ochrietor

Department Chair

Dr. James Gelsleichter

College Dean

Dr. Kaveri Subrahmanyam

Abstract

NGLY1 deficiency is a rare congenital disorder caused by mutations in the NGLY1 gene, which encodes an enzyme responsible for deglycosylating misfolded glycoproteins prior to proteasomal degradation. Affected individuals exhibit severe neurological and developmental impairments, including intellectual disability, movement disorder accompanied by severely diminished tear production (Alacrima), increased liver transaminases, and seizures. Despite extensive research on pathways disrupted by NGLY1 loss, the role of Wnt signaling, a critical regulator of neurodevelopment, remains unexplored. Here, we investigated whether NGLY1 deficiency alters Wnt pathway activity in mouse embryonic fibroblasts (MEFs). Transcriptomic analysis revealed downregulation of Wnt target genes and reduced β-catenin, a protein critical for the Wnt signaling pathway, in NGLY1-deficient MEFs. To test reversibility, we treated mutant and wild-type MEFs with a Wnt agonist and assessed β-catenin localization and Wnt target gene expression using RT-qPCR and immunofluorescence imaging. Our results demonstrated that pharmacological inhibition of GSK3, a key negative regulator of Wnt signaling, using CHIR99021, significantly increased cell viability, promoted β-catenin accumulation in both cytoplasmic and nuclear compartments, and upregulated the expression of Wnt target genes in NGLY1-deficient mouse embryonic fibroblasts. These findings identify Wnt signaling suppression as a novel consequence of NGLY1 deficiency and highlight GSK3 inhibition as a potential therapeutic strategy to restore Wnt pathway activity and mitigate cellular phenotypes associated with this disorder.

Available for download on Wednesday, January 06, 2027

Share

COinS